BD named Vitor Roque as chief financial officer Thursday, ending the medtech company’s seven-month search for a permanent ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...

Medical technology company Becton, Dickinson and Company (NYSE:BDX) announced in Q1 CY2026, with sales up 5.2% year on year ...

BD (NYSE:BDX) today announced the appointment of a new CFO alongside Street-beating second-quarter financial results.

BD’s new MiniDraw diagnostic devices could let pharmacists—and, one day, maybe patients—manage blood testing needs and monitor health conditions. BD received its FDA authorizations for two blood draw ...

The uplifted FY26 outlook reflects a reversal on Q1 FY26, in which BD trimmed its outlook due to impacts from the sale of its ...

After nearly a century spent building out its portfolio of insulin pens and syringes, BD is finally ready to let its diabetes care business leave the nest. While reporting financial results for the ...

Waters plans to combine with the Biosciences & Diagnostic Solutions business of BD (Becton, Dickinson & Co.), the companies said, in a $17.5 billion deal that would be the year’s largest within life ...

Dubai, United Arab Emirates – The Dubai branch of BD (Becton, Dickinson, and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will mark its presence at Arab ...

Becton Dickinson & Co. is set to make additional investments in its U.S. manufacturing network to add capacity for critical medical devices. “BD has a longstanding history as a leading U.S.